Obesity drugs seem to be everywhere these days. Just last week, Novo Nordisk announced that it was halting its study of semaglutide early for efficacy. The phase 3b FLOW trial explored the effects of once-weekly injectable semaglutide on kidney outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). Over the weekend,…